TY - JOUR
T1 - A novel transplantable model of lung cancer-associated tissue loss and disrupted muscle regeneration
AU - Arneson-Wissink, Paige C.
AU - Ducharme, Alexandra M.
AU - Doles, Jason D.
N1 - Funding Information:
J.D. was supported by the National Institute of Health/National Institute of Arthritis, Musculoskeletal and Skin Diseases (NIH/NIAMS) R00AR66696, Mayo Clinic start-up funds, Career Development Awards from the Mayo Clinic SPORE in Pancreatic Cancer (NIH/National Cancer Institute (NCI) CA102701), and the American Association for Cancer Research/Pancreatic Cancer Action Network. P.C.A was supported by the Mayo Clinic Regenerative Sciences Training Program (RSTP).
Publisher Copyright:
© 2020 The Author(s).
PY - 2020/3/9
Y1 - 2020/3/9
N2 - Background: Cancer-associated muscle wasting (CAW), a symptom of cancer cachexia, is associated with approximately 20% of lung cancer deaths and remains poorly characterized on a mechanistic level. Current animal models for lung cancer-associated cachexia are limited in that they (1) primarily employ flank transplantation methods, (2) have short survival times not reflective of the patient condition, and (3) are typically performed in young mice not representative of mean patient age. This study investigates a new model for lung cancer-associated cachexia that can address these issues and also implicates muscle regeneration as a contributor to CAW. Methods: We used tail vein injection as a method to introduce tumor cells that seed primarily in the lungs of mice. Body composition of tumor-bearing mice was longitudinally tracked using NMR-based, echo magnetic resonance imaging (echoMRI). These data were combined with histological and molecular assessments of skeletal muscle to provide a complete analysis of muscle wasting. Results: In this new lung CAW model, we observed (1) progressive loss in whole body weight, (2) progressive loss of lean and fat mass, (3) a circulating cytokine/inflammatory profile similar to that seen in other models of CAW, (4) histological changes associated with muscle wasting, and (5) molecular changes in muscle that implicate suppression of muscle repair/regeneration. Finally, we show that survival can be extended without lessening CAW by titrating injected cell number. Conclusions: Overall, this study describes a new model of CAW that could be useful for further studies of lung cancer-associated wasting and accompanying changes in the regenerative capacity of muscle. Additionally, this model addresses many recent concerns with existing models such as immunocompetence, tumor location, and survival time.
AB - Background: Cancer-associated muscle wasting (CAW), a symptom of cancer cachexia, is associated with approximately 20% of lung cancer deaths and remains poorly characterized on a mechanistic level. Current animal models for lung cancer-associated cachexia are limited in that they (1) primarily employ flank transplantation methods, (2) have short survival times not reflective of the patient condition, and (3) are typically performed in young mice not representative of mean patient age. This study investigates a new model for lung cancer-associated cachexia that can address these issues and also implicates muscle regeneration as a contributor to CAW. Methods: We used tail vein injection as a method to introduce tumor cells that seed primarily in the lungs of mice. Body composition of tumor-bearing mice was longitudinally tracked using NMR-based, echo magnetic resonance imaging (echoMRI). These data were combined with histological and molecular assessments of skeletal muscle to provide a complete analysis of muscle wasting. Results: In this new lung CAW model, we observed (1) progressive loss in whole body weight, (2) progressive loss of lean and fat mass, (3) a circulating cytokine/inflammatory profile similar to that seen in other models of CAW, (4) histological changes associated with muscle wasting, and (5) molecular changes in muscle that implicate suppression of muscle repair/regeneration. Finally, we show that survival can be extended without lessening CAW by titrating injected cell number. Conclusions: Overall, this study describes a new model of CAW that could be useful for further studies of lung cancer-associated wasting and accompanying changes in the regenerative capacity of muscle. Additionally, this model addresses many recent concerns with existing models such as immunocompetence, tumor location, and survival time.
KW - Cachexia
KW - Cancer-associated muscle wasting
KW - Lung cancer
KW - Skeletal muscle
UR - http://www.scopus.com/inward/record.url?scp=85081529209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081529209&partnerID=8YFLogxK
U2 - 10.1186/s13395-020-00225-6
DO - 10.1186/s13395-020-00225-6
M3 - Article
C2 - 32151276
AN - SCOPUS:85081529209
SN - 2044-5040
VL - 10
JO - Skeletal Muscle
JF - Skeletal Muscle
IS - 1
M1 - 6
ER -